UBS AM’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-188,807
| Closed | -$13.6M | – | 3850 |
|
|
2025
Q4 | $13.6M | Buy |
188,807
+14,812
| +9% | +$957K | ﹤0.01% | 1006 |
|
|
2025
Q3 | $7.58M | Sell |
173,995
-221,970
| -56% | -$8.97M | ﹤0.01% | 1178 |
|
|
2025
Q2 | $11.2M | Buy |
395,965
+38,247
| +11% | +$1.14M | ﹤0.01% | 1301 |
|
|
2025
Q1 | $10.6M | Buy |
357,718
+25,329
| +8% | +$789K | ﹤0.01% | 1199 |
|
|
2024
Q4 | $9.67M | Sell |
332,389
-16,452
| -5% | -$688K | ﹤0.01% | 1263 |
|
|
2024
Q3 | $16M | Sell |
348,841
-1,524
| -0.4% | -$66.1K | ﹤0.01% | 1031 |
|
|
2024
Q2 | $14.3M | Buy |
350,365
+270,067
| +336% | +$7.75M | ﹤0.01% | 994 |
|
|
2024
Q1 | $2.05M | Sell |
80,298
-10,867
| -12% | -$170K | ﹤0.01% | 1685 |
|
|
2023
Q4 | $825K | Hold |
91,165
| – | – | ﹤0.01% | 2127 |
|
|
2023
Q3 | $582K | Buy |
91,165
+34,859
| +62% | +$300K | ﹤0.01% | 2234 |
|
|
2023
Q2 | $864K | Hold |
56,306
| – | – | ﹤0.01% | 2067 |
|
|
2023
Q1 | $864K | Sell |
56,306
-3,871
| -6% | -$85.2K | ﹤0.01% | 2067 |
|
|
2022
Q4 | $1.34M | Buy |
60,177
+36,455
| +154% | +$544K | ﹤0.01% | 1715 |
|
|
2022
Q3 | $387K | Hold |
23,722
| – | – | ﹤0.01% | 2433 |
|
|
2022
Q2 | $345K | Hold |
23,722
| – | – | ﹤0.01% | 2430 |
|
|
2022
Q1 | $438K | Sell |
23,722
-9,556
| -29% | -$162K | ﹤0.01% | 2502 |
|
|
2021
Q4 | $791K | Buy |
33,278
+23,722
| +248% | +$567K | ﹤0.01% | 2335 |
|
|
2021
Q3 | $235K | Buy |
+9,556
| New | +$208K | ﹤0.01% | 2665 |
|
Other funds holding RNAM
UBS AM's RNAM Position: Q1 2026 in Review
UBS AM sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 188,807 shares — an estimated $13.6M sold.
UBS AM first reported a position in RNAM in Q3 2021 and held it in 18 quarters. The position peaked at $16M in Q3 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- UBS AM reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- UBS AM sold 188,807 Avidity Biosciences shares in Q1 2026, an estimated $13.6M.
- UBS AM first reported a position in Avidity Biosciences in Q3 2021 and held it in 18 quarters.
- UBS AM's Avidity Biosciences position peaked at $16M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.